Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Enrichment of circulating interleukin‐17–secreting interleukin‐23 receptor–positive γ/δ T cells in patients with active ankylosing spondylitis
Tony Kenna, Stuart I. Davidson, Ran Duan, et al.
Arthritis & Rheumatism (2011) Vol. 64, Iss. 5, pp. 1420-1429
Closed Access | Times Cited: 243

Showing 1-25 of 243 citing articles:

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Dominique Baeten, Joachim Sieper, J. Braun, et al.
New England Journal of Medicine (2015) Vol. 373, Iss. 26, pp. 2534-2548
Open Access | Times Cited: 903
Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci
Adrián Cortés, James L. Hadler, John Pointon, et al.
Nature Genetics (2013) Vol. 45, Iss. 7, pp. 730-738
Open Access | Times Cited: 804
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
Dominique Baeten, Xenofon Baraliakos, J. Braun, et al.
The Lancet (2013) Vol. 382, Iss. 9906, pp. 1705-1713
Closed Access | Times Cited: 568
γδT17 Cells Promote the Accumulation and Expansion of Myeloid-Derived Suppressor Cells in Human Colorectal Cancer
Pin Wu, Dang Wu, Chao Ni, et al.
Immunity (2014) Vol. 40, Iss. 5, pp. 785-800
Open Access | Times Cited: 516
IL-17 in Chronic Inflammation: From Discovery to Targeting
Audrey Beringer, Mélissa Noack, Pierre Miossec
Trends in Molecular Medicine (2016) Vol. 22, Iss. 3, pp. 230-241
Closed Access | Times Cited: 376
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Dominique Baeten, Mikkel Østergaard, James Cheng‐Chung Wei, et al.
Annals of the Rheumatic Diseases (2018) Vol. 77, Iss. 9, pp. 1295-1302
Open Access | Times Cited: 324
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados, et al.
The Lancet (2018) Vol. 392, Iss. 10163, pp. 2441-2451
Open Access | Times Cited: 303
Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease
Veronique Chachay, Graeme A. Macdonald, Jennifer Martin, et al.
Clinical Gastroenterology and Hepatology (2014) Vol. 12, Iss. 12, pp. 2092-2103.e6
Closed Access | Times Cited: 270
Pathogenesis of ankylosing spondylitis — recent advances and future directions
Vidya Ranganathan, Eric Gracey, Matthew A. Brown, et al.
Nature Reviews Rheumatology (2017) Vol. 13, Iss. 6, pp. 359-367
Closed Access | Times Cited: 265
Interleukin‐17+CD8+ T Cells Are Enriched in the Joints of Patients With Psoriatic Arthritis and Correlate With Disease Activity and Joint Damage Progression
Bina Menon, Nicola Gullick, Gina Walter, et al.
Arthritis & Rheumatology (2014) Vol. 66, Iss. 5, pp. 1272-1281
Open Access | Times Cited: 258
IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis
Eric Gracey, Zoya Qaiyum, Ibrahim Almaghlouth, et al.
Annals of the Rheumatic Diseases (2016) Vol. 75, Iss. 12, pp. 2124-2132
Closed Access | Times Cited: 245
Regulation of Osteoblast Differentiation by Cytokine Networks
Dulshara Sachini Amarasekara, Sumi Kim, Jaerang Rho
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 6, pp. 2851-2851
Open Access | Times Cited: 245
Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
J. Braun, Xenofon Baraliakos, Atul Deodhar, et al.
Annals of the Rheumatic Diseases (2016) Vol. 76, Iss. 6, pp. 1070-1077
Open Access | Times Cited: 241
Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview
Claudia Schinocca, Chiara Rizzo, Serena Fasano, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 241
Ankylosing spondylitis: an autoimmune or autoinflammatory disease?
Daniele Mauro, Ranjeny Thomas, Giuliana Guggino, et al.
Nature Reviews Rheumatology (2021) Vol. 17, Iss. 7, pp. 387-404
Closed Access | Times Cited: 225
Update on Ankylosing Spondylitis: Current Concepts in Pathogenesis
Judith A. Smith
Current Allergy and Asthma Reports (2014) Vol. 15, Iss. 1
Closed Access | Times Cited: 218
Review: The Interleukin‐23/Interleukin‐17 Axis in Spondyloarthritis Pathogenesis: Th17 and Beyond
Judith A. Smith, Robert A. Colbert
Arthritis & Rheumatology (2013) Vol. 66, Iss. 2, pp. 231-241
Open Access | Times Cited: 213
HLA-B27 misfolding and ankylosing spondylitis
Robert A. Colbert, Tri Tran, Gerlinde Layh‐Schmitt
Molecular Immunology (2013) Vol. 57, Iss. 1, pp. 44-51
Open Access | Times Cited: 206
The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
Dennis McGonagle, Iain B. McInnes, Bruce Kirkham, et al.
Annals of the Rheumatic Diseases (2019) Vol. 78, Iss. 9, pp. 1167-1178
Open Access | Times Cited: 206
Interleukin‐23–Dependent γ/δ T Cells Produce Interleukin‐17 and Accumulate in the Enthesis, Aortic Valve, and Ciliary Body in Mice
Annika Reinhardt, Tetyana Yevsa, Tim Worbs, et al.
Arthritis & Rheumatology (2016) Vol. 68, Iss. 10, pp. 2476-2486
Open Access | Times Cited: 195
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen‐Week Results From a Phase III Randomized, Double‐Blind, Placebo‐Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors
Atul Deodhar, Denis Poddubnyy, César Pacheco‐Tena, et al.
Arthritis & Rheumatology (2018) Vol. 71, Iss. 4, pp. 599-611
Open Access | Times Cited: 183
Effects of the IL-23–IL-17 pathway on bone in spondyloarthritis
Ellen M. Gravallese, Georg Schett
Nature Reviews Rheumatology (2018) Vol. 14, Iss. 11, pp. 631-640
Closed Access | Times Cited: 182
Activation of the interleukin-23/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis
Zhenyu Zhong, Guannan Su, Aize Kijlstra, et al.
Progress in Retinal and Eye Research (2020) Vol. 80, pp. 100866-100866
Closed Access | Times Cited: 166
Psoriatic arthritis from a mechanistic perspective
Georg Schett, Proton Rahman, Christopher T. Ritchlin, et al.
Nature Reviews Rheumatology (2022) Vol. 18, Iss. 6, pp. 311-325
Closed Access | Times Cited: 90
Psoriatic Arthritis: Pathogenesis and Targeted Therapies
Ana Belén Azuaga, Julio Ramírez, Juan D. Cañete
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4901-4901
Open Access | Times Cited: 69
Page 1 - Next Page

Scroll to top